Announced Wed, 15 Jul · 17:55 IST
Subsidiary faces three drug license suspension orders in Karnataka
Compliance View source PDF
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.5%1-day move
₹805.00
prior close
₹805.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.2+0.2—-0.5-0.5-1.7-11.7-11.1-10.6————
Up moveDown movePending
AI summary
MedPlus subsidiary Optival Health Solutions received three drug license suspension orders from the Karnataka Drug Control Administration for stores at Sarakki JP Nagar Metro, Jaraganahalli, and Chikkodi under Rule 65 of the Drugs and Cosmetics Act. Suspensions range from one to two days. Total potential revenue loss is around Rs 1.59 lacs, which is negligible for the company.
Likely market impact
Minimal financial impact. A combined revenue loss of about Rs 1.59 lacs is negligible for MedPlus and likely of no concern to shareholders.